• BioAge Labs began dosing the first participant in QUELL-DME, a Phase 2 trial of oral NLRP3 inhibitor BGE-102 for diabetic macular edema.
• Results have not been presented; topline data are expected in the second half of 2027.
• The study will assess whether daily oral treatment can improve vision, used alone or alongside standard anti-VEGF eye injections.
• Roughly 180 adults are enrolled in a randomized, controlled design with a 12-week treatment period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080800PRIMZONEFULLFEED9822534) on September 08, 2026, and is solely responsible for the information contained therein.